Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Latest in Blood
Plenary Papers
Catharina Conrad; Mélia Magnen; Jessica Tsui; Harrison Wismer; Mohammad Naser; Urmila Venkataramani; Bushra Samad; Simon J. Cleary; Longhui Qiu; Jennifer J. Tian; Marco De Giovanni; Nicole Mende; Andrew D. Leavitt; Emmanuelle Passegué; Elisa Laurenti; Alexis J. Combes; Mark R. Looney
First Edition
Lara Wahlster; Lucy A Godley; Jason X Cheng; Michael W Drazer; Christopher R. Reilly; Geraldine S Pinkus; Jared H Rowe; Nina Weichert-Leahey; Robert Grant Rowe; Lev Gorfinkel; Karyn Jean Brundige; Franziska Wachter; Luana Miria Messa; Alan D Michelson; Alan B. Cantor; Akiko Shimamura; Jacob R Bledsoe
Clinical Trials and Observations
Mark J. Levis; Mehdi Hamadani; Brent R. Logan; Richard J. Jones; Anurag K. Singh; Mark R. Litzow; John R. Wingard; Esperanza B. Papadopoulos; Alexander E. Perl; Robert J. Soiffer; Celalettin Ustun; Masumi Ueda Oshima; Geoffrey L. Uy; Edmund K. Waller; Sumithira Vasu; Melhem Solh; Asmita Mishra; Lori S. Muffly; Hee-Je Kim; Matthias Stelljes; Yuho Najima; Masahiro Onozawa; Kirsty Thomson; Arnon Nagler; Andrew H. Wei; Guido Marcucci; Caroline Chen; Nahla Hasabou; Matt Rosales; Jason Hill; Stanley C. Gill; Rishita Nuthethi; Denise King; Adam Mendizabal; Steven M. Devine; Mary M. Horowitz; Yi-Bin Chen

Advertisement intended for health care professionals


170,000 citations
earned in 2023



Featured Content

Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML

STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia

CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia

GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia

The JAK2 46/1 haplotype influences PD-L1 expression

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals